Compare FUL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUL | TARS |
|---|---|---|
| Founded | 1887 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | FUL | TARS |
|---|---|---|
| Price | $58.47 | $79.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $68.50 | ★ $73.63 |
| AVG Volume (30 Days) | 382.3K | ★ 438.7K |
| Earning Date | 01-14-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $3,502,085,000.00 | $366,100,000.00 |
| Revenue This Year | N/A | $139.46 |
| Revenue Next Year | $2.36 | $49.91 |
| P/E Ratio | $28.30 | ★ N/A |
| Revenue Growth | N/A | ★ 182.44 |
| 52 Week Low | $47.56 | $38.51 |
| 52 Week High | $77.77 | $83.47 |
| Indicator | FUL | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 63.78 |
| Support Level | $55.08 | $77.51 |
| Resistance Level | $59.43 | $83.47 |
| Average True Range (ATR) | 1.44 | 3.56 |
| MACD | 0.27 | 0.26 |
| Stochastic Oscillator | 77.93 | 70.63 |
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.